HC Wainwright & Co. Initiates Coverage On Xenon Pharmaceuticals with Buy Rating, Announces Price Target of $53
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Xenon Pharmaceuticals with a Buy rating and set a price target of $53.
October 01, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Xenon Pharmaceuticals with a Buy rating and a price target of $53, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $53 by a reputable firm like HC Wainwright & Co. suggests a positive outlook for Xenon Pharmaceuticals. This can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100